OneOncology

Community oncology leaders navigate challenges in value-based care under the Enhancing Oncology Model, facing performance payment uncertainties and evolving drug markets.

The FDA's removal of REMS for CAR T-cell therapies enhances access for community oncology, paving the way for innovative treatments and improved patient outcomes.

OneOncology appoints Ian Wong as COO, enhancing its mission to provide accessible, high-quality cancer and urology care through innovative practices.

OneOncology appoints Michael Byrne, DO, to enhance access to CAR T-cell therapy, revolutionizing cancer treatment in local practices nationwide.

Artificial intelligence (AI) transforms oncology by enhancing clinical decision-making, improving patient outcomes, and shaping future health care training, as discussed by experts at Tennessee Oncology's “Tech Innovations in Community Oncology."

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."

Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering Cancer Center, and New York Cancer & Blood Specialists discussed the power of collaboration in cancer care, highlighting partnerships that enhance patient outcomes and resource sharing in community practices.

New York Oncology and Hematology becomes the 27th practice in OneOncology.

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

The Nashville-based managed services organization now serves 1300 providers and 747,000 patients across 420 sites of care.

The American Journal of Managed Care®’s Strategic Alliance Partnerships provide valuable insights into health care trends through collaborations with health systems, payers, oncology practices, and more.

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.

Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.

A statement about the acquisition promises that Navigating Cancer will operate independently with no differences in service regardless of a practice's status with a management service organization.

It’s hard for practicing oncologists to stay on top of the latest clinical data, but good partnerships and clinical decision support tools can assist.

United Urology Group, with 4 practices in Maryland, Colorado, Arizona, and Tennessee, has agreed to be acquired by OneOncology, which last year was acquired by TPG and AmeriSourceBergen in a $2.1 billion transaction.